Patient characteristics: LT population
| Characteristic . | Patients groups according to follow-up period . | ||
|---|---|---|---|
| Less than 1 y . | 1 to 5 y . | More than 5 y . | |
| Patients, no. | 5 | 8 | 8 |
| Demography | |||
| Sex, no. M/F | 2/3 | 4/4 | 5/3 |
| Age, y | 44.8 ± 9.7 | 54.6 ± 10.6 | 56.9 ± 6.0 |
| Follow-up period, mo | 5.8 ± 4.7 | 45 ± 12.4 | 177.2 ± 58.3 |
| Medical indication for the transplantation | |||
| Viral cirrhosis | 1 (20) | 5 (62.5) | 8 (100) |
| Alcoholic cirrhosis | 2 (40) | 0 | 0 |
| Hyperoxaluria type 1/amyloidosis neuropathy | 0 | 2 (25) | 0 |
| Autoimmune cirrhosis | 0 | 1 (12.5) | 0 |
| Other | 2 (40) | 0 | 0 |
| Viral hepatic recurrence | |||
| Hepatitis B virus | 0 | 0 | 1 (12.5) |
| Hepatitis C virus | 0 | 3 (37.5) | 2 (25) |
| Immunosuppressive treatment | |||
| Cyclosporin A | 0 | 2 (25) | 7 (87.5) |
| FK506 | 5 (100) | 6 (75) | 1 (12.5) |
| Corticosteroid | 5 (100) | 7 (87.5) | 5 (62.5) |
| Mycophenolate mofetil | 5 (100) | 7 (87.5) | 5 (62.5) |
| Azathioprin | 0 | 0 | 1 (12.5) |
| sHLA-G, ng/mL | |||
| sHLA-G1 + HLA-G5 | 102.6 ± 6.2 | 116.5 ± 35.9 | 134.1 ± 50.3 |
| HLA-G5 | 97 ± 11.9 | 80.5 ± 27.3 | 110.9 ± 20.9 |
| Rejection | |||
| Acute rejection | 0 | 2 (25) | 1 (12.5) |
| Chronic rejection | 0 | 1 (12.5) | 0 |
| Characteristic . | Patients groups according to follow-up period . | ||
|---|---|---|---|
| Less than 1 y . | 1 to 5 y . | More than 5 y . | |
| Patients, no. | 5 | 8 | 8 |
| Demography | |||
| Sex, no. M/F | 2/3 | 4/4 | 5/3 |
| Age, y | 44.8 ± 9.7 | 54.6 ± 10.6 | 56.9 ± 6.0 |
| Follow-up period, mo | 5.8 ± 4.7 | 45 ± 12.4 | 177.2 ± 58.3 |
| Medical indication for the transplantation | |||
| Viral cirrhosis | 1 (20) | 5 (62.5) | 8 (100) |
| Alcoholic cirrhosis | 2 (40) | 0 | 0 |
| Hyperoxaluria type 1/amyloidosis neuropathy | 0 | 2 (25) | 0 |
| Autoimmune cirrhosis | 0 | 1 (12.5) | 0 |
| Other | 2 (40) | 0 | 0 |
| Viral hepatic recurrence | |||
| Hepatitis B virus | 0 | 0 | 1 (12.5) |
| Hepatitis C virus | 0 | 3 (37.5) | 2 (25) |
| Immunosuppressive treatment | |||
| Cyclosporin A | 0 | 2 (25) | 7 (87.5) |
| FK506 | 5 (100) | 6 (75) | 1 (12.5) |
| Corticosteroid | 5 (100) | 7 (87.5) | 5 (62.5) |
| Mycophenolate mofetil | 5 (100) | 7 (87.5) | 5 (62.5) |
| Azathioprin | 0 | 0 | 1 (12.5) |
| sHLA-G, ng/mL | |||
| sHLA-G1 + HLA-G5 | 102.6 ± 6.2 | 116.5 ± 35.9 | 134.1 ± 50.3 |
| HLA-G5 | 97 ± 11.9 | 80.5 ± 27.3 | 110.9 ± 20.9 |
| Rejection | |||
| Acute rejection | 0 | 2 (25) | 1 (12.5) |
| Chronic rejection | 0 | 1 (12.5) | 0 |
Patients (n = 21) were separated into 3 groups based on the time interval between the date of the transplantation and the blood sampling to measure sHLA-G plasma levels. Data are means plus or minus SD or number of patients (%). There was no significant difference in sHLA-G plasma levels between follow-up period groups, except between groups 1 to 5 years and more than 5 years for HLA-G5 (P=.01).